Back to Journals » Research and Reviews in Parkinsonism » Volume 10

Challenges and Opportunities in Atypical Parkinsonian Syndromes: Call to Action

Authors Roach M, Chou JW, Lavin B, Maclean JR

Received 21 August 2019

Accepted for publication 23 December 2019

Published 10 January 2020 Volume 2020:10 Pages 1—6

DOI https://doi.org/10.2147/JPRLS.S228108

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 3

Editor who approved publication: Dr Peter Hedera


Meaghan Roach, 1 Jacquelyn W Chou, 1 Bruce Lavin, 2 J Ross Maclean 1

1Precision Health Economics, Los Angeles, CA, USA; 2UCB, Inc, Smyrna, GA, USA

Correspondence: Meaghan Roach
Precision Health Economics, 11100 Santa Monica Blvd, Suite 500, Los Angeles, CA 90025, USA
Email meaghan.roach@precisionxtract.com

Abstract: Neurodegenerative diseases are a leading cause of disability and death in the United States, and the burden of rare neurodegenerative conditions such as atypical Parkinsonian syndromes is expected to grow in the coming years as the size of the older population increases at an unprecedented rate. Atypical Parkinsonian syndromes encompass a collective of rare neurodegenerative diseases that are often misdiagnosed as Parkinson’s disease due to similar signs and symptoms. These syndromes include progressive supranuclear palsy (PSP), multiple system atrophy (MSA), and corticobasal degeneration (CBD), and are characterized by rapid disease progression and decreased life expectancy. In this paper, we describe the substantial burden atypical Parkinsonian syndromes pose to the healthcare system and patients attributable to challenges in diagnosis, ineffective treatment options, and rapid functional decline. Despite increased understanding and recognition of these disorders, there remains significant unmet need for patients with atypical Parkinsonian syndromes. We provide recommendations to policymakers to support access to effective disease management of atypical Parkinsonian syndromes through legislative efforts that i) prioritize development of disease-modifying treatments, ii) focus on objectively assessing disease progression in addition to symptom management, and iii) bring forth economic frameworks that capture the full value of treatments.

Keywords: atypical Parkinsonian syndromes, progressive supranuclear palsy, multiple system atrophy, corticobasal degeneration, disease-modifying treatments


Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]